Free Publication in 2019
Received: November 29, 2018 | Accepted: March 07, 2019 | Published: March 12, 2019
OBM Neurobiology 2019, Volume 3, Issue 1, doi:10.21926/obm.neurobiol.1901022
Academic Editor: Antonio Meola
Special Issue: Tumors of the Central Nervous System
Recommended citation: Zhou T, Khan S, Firestein R, Downie P, Cain JE. Diffuse Intrinsic Pontine Glioma: Translation of Genomic Knowledge to Clinical Practice. OBM Neurobiology 2019;3(1):8; doi:10.21926/obm.neurobiol.1901022.
© 2019 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.
DIPGs are aggressive high-grade gliomas (HGGs) derived from glial cells located in the pons of the brainstem with varying degrees of infiltration into neighboring structures. DIPG accounts for 80% of all brainstem gliomas and was traditionally classified based on anatomical location, radiographic location and where possible, by histopathology. The most recent edition of the World Health Organization (WHO) Classification of CNS Tumors published in 2016 uses molecular information in addition to histopathology and has redefined the majority of DIPGs as diffuse midline glioma, H3 K27M-mutant. Biopsied DIPGs have demonstrated the heterogenous histopathological spectrum of this tumor. They are usually high-grade astrocytoma’s with increased microvascular proliferation, and are often associated with increased mitosis and necrosis, although up to a quarter of those biopsied lack these features and appear to be low grade on histological examination. Regardless of its histopathological grade at diagnosis, tumors under the DIPG/diffuse midline glioma, H3 K27M-mutant classification are aggressive in nature and have a poor overall prognosis .
DIPGs most commonly affect younger children with a peak incidence between the ages of 6 to 9, and a male to female ratio of 1:1. Patients typically present with a brief history of clinical symptoms and signs consistent with brainstem dysfunction, supported by typical radiologic findings on magnetic resonance imaging (MRI) (Table 1). Clinical signs in over 50% of presentations involve the classical triad of: 1) cranial nerve deficits (most commonly affecting the sixth and seventh cranial nerves resulting in facial asymmetry and diplopia); 2) cerebellar and bulbar signs (ataxia, dysmetria, drooling and dysarthria); and 3) long tract signs (hyperreflexia, upward going Babinski reflex and weakness) [4,5]. Once the diagnosis is confirmed, treatment options are limited. Patients with histopathologically confirmed DIPG on current treatment protocols have a median survival of just 8-10 months with virtually all children succumbing within 2 years of diagnosis . A small number of long-term survivors (LTSs) have been reported in various studies and case series and were systematically reviewed by Hoffman et al in 2018 [7,8]. Although this review excluded LTSs reported with MRI findings atypical for DIPG, many still lacked tissue biopsy to prove the diagnosis. Intriguingly, it does suggest that children presenting under the age of 3 or over the age of 10 had a better prognosis, with cranial nerve palsy, ring enhancement, extrapontine extension and necrosis at presentation being negative prognostic factors. Owing to its aggressive nature, DIPG remains the primary cause of death from brain tumors diagnosed in children. As such, it poses a significant challenge to all clinicians involved in the care of these children.
DIPG was first described by Dr Harris and Dr Newcomb in a pediatric case report in 1926. The 14-year-old boy presented following a minor head injury, and over the ensuing weeks was reported to have rapidly progressive cranial nerve palsies and pyramidal tract dysfunction, and he died within two months of presentation. The diagnosis of a pontine glioma was made clinically and the diffuse nature was confirmed histologically at post mortem . Until recently, research initiatives into DIPG have been limited to therapies (radiation and chemotherapy) with limited benefit in other forms of HGG [10,11]. Owing to the anatomical position of the tumor in the ventral pons, surgical interventions have had little role to play in its management . There is no role for chemotherapy. Steroids may alleviate symptoms transiently but have the burden of severe side effects. Radiation is used as a palliative measure for symptom control, and has demonstrated a minimal survival benefit of a few months in some studies [13,14,15].
Table 1 Clinical and radiological features of DIPG.
Traditional chemotherapies have proven to be ineffective in the treatment of DIPG, presumably due to poor blood brain barrier permeability and/or distribution throughout the tumor mass. Regardless, conventional cytotoxics have continued to be trialed, alone and in combination, but without effect. Interestingly, a limited study investigating neoadjuvant high-dose methotrexate, BCNU, cisplatin and tamoxifen administered to DIPG patients until progressive disease, then followed by radiotherapy, reported an encouraging median overall survival of 17 months . Since survival following radiotherapy is comparable to historical controls, the overall improved survival duration is likely attributed to upfront chemotherapy. However, long-term survival remained poor and the use of multi-agent medical therapies has not been adopted into routine clinical care.
Corticosteroids are widely used as supportive treatment to manage symptoms but do not have any effect on the tumor tissue itself. Administration of dexamethasone at the time of diagnosis will decrease edema of the surrounding brainstem and pons, with often rapid improvement in symptoms and signs. However, the side-effects of prolonged administration of dexamethasone can be a clinical challenge resulting in a compromised quality of life made more difficult with the return of symptoms and signs once they are withdrawn .
DIPGs typically arise in the pons resulting in destruction of intrinsic nerve fiber tracts with spread to the adjacent midbrain, medulla and cerebellar peduncles. Cranial nerves VI and VII are most commonly affected, although cranial nerves V, X and XI can also be commonly affected as the disease progresses. Owing to the central brainstem being involved and the diffuse nature of the tumor, surgical resection is not recommended [12,18,19,20].
It should be noted that surgical intervention may only be considered after referral to a highly specialized neurosurgical team, in conjunction with pediatric neuro-oncologists, before any treatment is initiated. In the past, the paucity of available surgical tissue has in part hindered the development of suitable preclinical models for research. Until recently, DIPG tissue acquisition was difficult due to the morbidity associated with the anatomical site of the tumor and tissue was only acquired at post mortem under consent and often following extensive treatment.
In 2007, Roujeau et al. published the first major report of upfront stereotactic biopsy of DIPG patients. The study found that of the twenty-four patients studied, only two suffered deficits from the procedure, with both being transient and lasting less than two months. Importantly, a histological diagnosis was made in all 24 patients, and that 22 had an infiltrative malignant glioma, with 1 having a pilocytic astrocytoma, and 1 having a low-grade glioma. This study concluded that tissue biopsies in DIPG have a high diagnostic yield associated with minimal morbidity and resulted in a consensus meeting in Paris in 2011 where it was agreed that biopsy of brain stem gliomas is technically safe with acceptable risks to inform on optimal therapeutic interventions . Since then, similar clinical studies have continued to prove that there is minimal risk of persistent morbidity or mortality associated with the procedure whilst providing valuable pathologic and histologic insights [22,23,24].
This important innovation has led to increasing numbers of recent trials incorporating genomic analysis into their treatment protocols as a core indicator for potential targeted treatment options. With increased willingness to biopsy, the increased availability of tissue has led to an exponential increase in our understandings of the genomic, transcriptomic and epigenetic landscapes of DIPG, and an increase in pre-clinical models. Tumor biopbsy will also enable direct analysis of treatment naïve and treatment resistant tissues from longitudinal samples of the same patient. Collectively, these resulting resources are leading to the rationalized introduction of new clinical trials for targeted therapies, which will be discussed in more detail below.
Detection of the Histone H3 mutations in CSF-derived tumor DNA from patients with diffuse midline glioma was first described in 2017 by Huang et al . In a small cohort of 6 diffuse midline glioma patients, sufficient CSF-derived tumor DNA was isolated from 5 of the patients and Histone H3 mutations were detected in 4 of these using Sanger sequencing. More recently, using digital droplet PCR, Histone H3 and additional driver mutations were detected in both CSF and plasma-derived tumor DNA from 48 diffuse midline glioma patients, all with matching tumor tissue . Furthermore, this approach was applied to the longitudinal surveillance of patients during their clinical management and showed that changes in circulating tumor DNA mutational allele frequencies accurately reflected tumor response to therapy. This highlights the potential use of patient-derived liquid biopsy as both a clinically relevant diagnostic and predictor of therapy response and disease progression in patients with DIPG.
To date, radiotherapy is the only therapeutic option to have demonstrated transient benefits in length of survival from diagnosis. Whilst not curative, and merely palliative, radiation therapy remains the standard of care treatment for children with DIPG. It is the only treatment repeatedly and reproducibly proven to provide temporary symptomatic relief and short-term progression control. Conventional radiotherapy targets the tumor volume plus a clear margin of 1 to 2 cm of adjacent neural tissue, accumulating a total dose between 54 Gy and 59.4 Gy over a period of 6 weeks with five treatment days per week, at a dose of approximately 1.8 Gy per fraction. However, despite significant radiological tumor shrinkage achieved with radiotherapy, the response is transient .
Furthermore, clinical trials have endeavored to improve survival rates through administration of higher doses of radiation and the use of adjunct chemotherapy and radiosensitizers, however survival and symptomatic benefits of these radiotherapy variations have shown no additional benefit [28,29]. Recent studies of radiotherapy in DIPG have instead focused on identifying the lowest radiation dose required to attain the same therapeutic effect in order to maximize quality of life by reducing the burden of treatment. Indeed, a recent Phase III trial investigating hypofractionated radiotherapy, cumulative dose of 39 Gy in daily fractions of 3 Gy in thirteen treatments over 2.6 weeks, resulted in nearly comparable outcomes to conventional fractionation but with less burden on patients . The potential for re-irradiation following disease progression has also become a recent area of interest, with several limited cohort studies reporting neurological improvement and improved median survival . Upcoming phase II clinical trials of a prospective nature with increased target populations are investigating the reproducibility and morbidity associated with this method.
Recent advances in next generation sequencing techniques and stereotactic biopsies to access tissues, has enabled the in-depth exploration of the potential genomic and molecular alterations underpinning DIPG tumorigenesis. Importantly, these studies have revealed distinct biological driver aberrations that could be therapeutically exploited. This includes recurrent mutations or amplification in genes associated with epigenetic regulation, cell signaling pathways, cell cycle regulation, and DNA repair mechanisms, often co-occurring in mutually exclusive combinations. Here, we will discuss the key alterations and their potential to be therapeutically targeted.
The most significant advance in our understanding of DIPG biology has come from the discovery of unique recurrent somatic heterozygous mutations in genes encoding for two different histone H3 variants, H3.1 (HIST1H3B, HIST1H3C) and H3.3 (H3F3A) that are essential for epigenetic control of gene expression . These mutually exclusive mutations in the histone H3 genes similarly result in a distinct single nucleotide variant leading to an amino acid substitution in the highly conserved N-terminal histone tail: lysine-to-methionine at position 27 (K27M). Collectively, H3K27M mutations occur in 74-93% of DIPG tumors [32,33,34,35,36,37]. The H3F3A mutation (H3.3K27M) is found in approximately two-thirds (56%-80%) of DIPGs and is associated with a later age of disease onset (7-10 years) and poorer overall survival (9 months) [32,33,35,38]. Interestingly, H3.3K27M mutations also exclusively occur in diffuse midline gliomas effecting the thalamus and spinal cord. In contrast, H3.1K27M mutations are restricted to approximately one-fifth (17-31%) of DIPGs, correlated with an earlier age of onset (4-6 years), distinct clinicopathological and radiological features, and slightly longer survival (15 months) [32,38].
Whilst the precise functions of H3K27M are still to be determined, evidence suggests that the mutation imparts a gain-of-function activity inhibiting the Polycomb repressive complex 2 (PRC2) via direct sequestration of the histone methyltransferase Enhancer of zeste homolog 2 (EZH2) resulting in a global reduction in H3K27me3 [39,40]. Despite a global hypomethylation phenotype in H3K27M DIPGs, selected genomic regions of histone hypermethylation (gain of H3K27me3) are also observed, particularly in intergenic regions. As expected, genes with aberrant gain or loss of H3K27me3 demonstrate decreased or increased expression, respectively, strongly implicating epigenetic control of gene expression as an underlying mechanism driving DIPG pathogenesis . Since epigenetic modifications are reversible, many studies have focused on the therapeutic potential of epigenetic modifiers. These include the use of inhibitors of H2K27 demethylases (JMJD3 and GSKJ4), histone deacetylase inhibitors (panobinostat and sodium valproate), catalytic EZH2 inhibitors (EPZ6438) and BET inhibitors, all which have shown promise in preclinical models (Table 2, Table 3).
Interestingly, H3.1K27M and H3.3K27M mutations co-occur with exclusive genetic alterations, likely accounting for the distinct clinical features described above. TP53 mutations, PDGRFA mutations/amplifications, amplification at 17p11.2 targeting TOP3A, amplification of CCND2, ATRX, ATM and ASXL1 mutations largely co-segregate with H3.3K27M. In contrast, H3.1K27M exclusively co-occurs with ACVR1 and BCOR mutations and an enrichment of downstream PI3K pathway mutations (PIK3CA and PIK3R1) [32,35,36,41]. Interestingly, MYCN/ID2 mutations are enriched in H3 wildtype DIPG . The specific functional importance of these co-segregating genomic alterations is now an area of intense investigation and pre-clinical results strongly suggest that combination therapy targeting both H3K27M and specific partner mutations will be necessary in the clinic.
Table 2 Genomic abnormalities in DIPG and the targeted therapies tested.
Table 3 Selected preclinical DIPG targeted drug studies (published up to June 2018).
Recurrent mutations and gene amplification involved in key mitogenic and developmental signaling pathways have been described in a significant proportion of DIPGs and are commonly found to coexist with H3 mutations. The more commonly affected pathways include the PDGF, EGFR and BMP pathways.
The platelet-derived growth factor (PDGF) signaling pathway is involved in the regulation of cell growth and division, and angiogenesis. PDGF ligands bind to the cell membrane protein tyrosine kinase receptors PDGRFA and PDGFRB leading to activation of other proteins by phosphorylation. PDGFRA is one of the commonly mutated PDGF receptors found in malignancies and is the most commonly mutated and/or amplified tyrosine kinase receptors in DIPG, occurring in 5% and 30% of tumors respectively [42,45,46,47]. PDGFRA mutations/amplification most commonly co-occur with H3.3K27M. The PDGFRA inhibitors, dasatinib and cabozanitinib, have been investigated in preclinical DIPG drug studies. These compounds have demonstrated cytostatic modes of action and are synergistic when administered together. However, PDGFRA inhibitors are known to have poor CNS penetration, limited primarily by drug efflux transporters. Further animal studies are necessary to investigate whether the co-administration of an efflux transporter inhibitor may improve CNS drug concentrations and subsequent drug efficacy. Inhibition of vascular endothelial growth factor (VEGF) is known to reduce downstream activation of PDGRA. VEGF inhibitors have been investigated in DIPG cell lines, so far with inconclusive results. Despite the preclinical data to date, the development of a genetic mouse model driven by PDGF-B overexpression, strongly supports a role for this pathway in DIPG tumorigenesis . Recent effort has also focused on targeting its downstream effector pathway, PI3K/AKT/mTOR, that is also strongly implicated in DIPG.
EGFR mutations and amplification are among the most common genetic aberrations found in adult glioblastomas but are scarcely found in DIPGs. It is therefore not surprising that despite the large number of clinical trials investigating EGFR-targeting agents, none have shown efficacy so far. Similarly, there are varying reports on the prevalence of other mutations in kinase pathways, including MET mutations, which are seen in a minority of DIPGs. Trials conducted so far have failed to prove their potential as a DIPG therapeutic target [45,59,60,61].
The bone morphogenetic protein (BMP) signaling pathway is affected in 20-30% of DIPGs, predominantly in the form of activating mutations in ACVR1, a gene encoding type I BMP receptor (ALK2), that exclusively co-occur with H3.1K27M. To date, 7 different ACVR1 mutations have been described in DIPG, resulting in ligand-independent constitutive activation of the pathway, upregulation of phosphorylated SMAD1/5 transcriptional effectors and upregulation of downstream BMP targets, leading to promotion of cell cycle progression via the RB and p21 pathways [33,37,88,89]. Similar gain-of-function mutations have been described in the rare inherited bone disease, fibro-dysplasia ossificans progressiva (FOP) . Despite significant biological differences between FOP and DIPG, including the inherited nature of FOP, the study of ACVR1 functions in FOP may be useful in the overall DIPG analysis. Limited ALK2 inhibitor drug studies have been performed on either tumor types and interpretation of results has been inconclusive. The role of ACVR1 in DIPG is yet to be determined . With the availability of highly-specific ALK2 inhibitors, further preclinical studies are necessary to investigate their effects on potentially susceptible DIPG cell lines.
Genetic abnormalities involving essential cellular pathways are also found in a third of DIPGs, commonly coexisting with oncogenic mutations in the histone genes or kinase pathways as accessory drivers. The more commonly affected pathways include the RB and PI3K-Akt pathways.
Genetic abnormalities in the RB pathway that are described in DIPG include focal deletion of RB itself, amplifications of CCND1/2/3 (cyclin D1/D2/D3), and downstream CDK4/6 (cyclin-dependent kinase 4/6), collectively occurring in approximately 30% of tumors [42,55,57]. These cellular proteins contribute to phosphorylation of RB and the coordination of G1/S cell cycle progression. The increased activity of these proteins contributes to tumor growth. The CDK4/6 inhibitor, palbociclib, has been studied in DIPG murine models demonstrating a cytostatic mechanism of action but with limited efficacy . As these abnormalities are often coexistent with other genetic aberrations, combination therapy may potentially prove to have greater effectiveness.
The PI3K/AKT/mTOR pathway is commonly implicated in glioblastoma as well as in other tumor types. Mutations in this pathway affect cellular signaling associated with control of the cell cycle and include alterations in tyrosine kinase receptors, growth factors, and interacting pathways including Ras/Raf/MEK/ERK. These mutations affect approximately 15% of DIPGs and include recurrent mutation/amplification of PIK3CA, mutations of PIK3R1, and mutation/loss of PTEN. Recently, there has been substantial preclinical activity in determining the efficacy of PI3K/mTOR inhibitors in DIPG, often in combination with other targeted agents. Inhibition of PI3K/AKT pathway with perifisone in combination with the MEK inhibitor, trametinib, synergistically reduced DIPG cell viability, while use of the dual HDAC/PI3K inhibitor, CUDC-907, as a radiosensitizer looks promising, acting by inhibiting radiation-induced DNA repair pathways [83,92]. However, more preclinical work is needed to further investigate the potential role of inhibiting these pathways, with particular consideration directed to ensuring adequate agent tumor penetration.
The Hedgehog pathway has been investigated as another potential therapeutic target owing to earlier studies demonstrating its upregulation in DIPG . However, these molecular abnormalities are uncommon, and found to be insufficient to cause DIPG formation in murine models. Although the role of the Hedgehog pathway in tumor formation remains unclear, studies into the efficacy of Hedgehog pathway inhibitors, including Smoothened inhibitors, are still currently being undertaken in clinical trials [2,93,94,95].
Mutations in the TP53 pathway are the second most common genetic aberration in DIPG with mutations or copy number alterations observed in 42-71% of tumors and can co-occur in the presence or absence of H3 mutations. Interestingly, PPM1D, encoding a phosphatase (WIP1) that negatively regulates p38 MAPK and is induced by TP53, is mutated in approximately 10% of DIPG. Functionally, PPM1D mutations are equivalent to TP53 mutations, and they are largely mutually exclusive with PPM1D mutations observed in 50% of DIPGs that are wildtype for TP53 [50,51,52,96]. These mutations appear to function primarily as accessory drivers in the oncogenic process and research into their therapeutic potential is scarce. However, they may have a role in therapeutic synergy with other agents in combination therapy.
Other DNA repair proteins found to be affected in DIPG include the PARP1/2 and WEE1 proteins. Their prevalence in DIPG cohorts has not yet been formally studied. Nonetheless, their potential as molecular targets have been studied in preclinical models with both PARP1 inhibitors and WEE1 inhibitors demonstrating radio-sensitization effects. Further studies are needed to investigate their clinical efficacy [66,67,68,71,72,97,98].
With the recent surge in our understanding of DIPG genomics, attention has now turned to translating this knowledge into meaningful therapeutic strategies using preclinical models. Several drug classes are currently being trialed in preclinical studies both in vitro, and in vivo using murine models (Table 3). Studies published to date have mainly tested agents targeting epigenetic dysregulation and aberrant kinase pathway activity, using targeted therapies either FDA-approved or in late-stage clinical trials for other tumor types. Many studies have shown therapeutic potential of targeted therapies in vitro. However, the cytostatic or cytotoxic effects observed in vitro only partially translate into in vivo murine models due to inability to efficiently cross the blood brain barrier, high levels of systemic toxicity owing to their wide-ranging effects on different pathways and cell types, and only modest improvements in survival. These findings, in part, highlight the critical importance of relevant and reliable in vitro and in vivo models that has until recently been lacking for DIPG.
Increased frequency of early post-mortem, stereotactic biopsies and refinement of DIPG culture conditions and supplementation has enabled the development of cohorts of patient-derived DIPG cell models. Slowly but surely these models are now becoming sufficient in number to accurately represent the heterogeneity of the disease and are often extensively characterized at a genomic level with accompanying clinical annotations [99,100]. These models have provided an invaluable resource to the research community with which to explore underlying biology and identify new therapeutic avenues. The accompanying genomic and molecular annotations of these models is now enabling the next wave of phenotype-genotype analyses to uncover primary genetic drivers of disease, relevance of co-occurring alterations and functional importance of targetable pathways, in a cohort and even patient-specific context [99,100]. However, the normal limitations of in vitro cell models also apply to DIPG. These include potential of the cells to genomically or molecularly “drift”, and responses to be different in the absence of supporting tissues and other signals, including immunomodulation. As a result, in vitro studies are often subsequently validated using in vivo disease models.
The availability of increased patient-derived cell models has also permitted the development of orthotopic cell-derived DIPG xenograft models that replicate the invasive nature of the disease and maintain key genomic and molecular characteristics. Direct injection of human DIPG cells into the fourth ventricle/pons of immune-deficient mice has not only enabled the interrogation of gene function and tumor biology but enabled evaluation of potential therapies on DIPG in situ, including an intact blood brain barrier, and potential systemic toxicities. Moreover, the labelling of tumor cells prior to injection, most commonly using luciferase constructs, to permit imaging, allows researchers to monitor tumor growth and response to therapy using longitudinal imaging techniques . Patient-derived orthotopic xenograft models, whereby patient tumor and stromal cells are injected without culture, also represents a valuable in vivo preclinical system. Typically, these patient-derived xenografts are maintained by serial passaging in immune-deficient mice to avoid any potential culture artefact. The limitation is related to absence of expression of reporters for imaging. Whilst these models remain the gold standard for in vivo investigation for DIPG preclinical studies, the use of immune-deficient mouse strains largely precludes the investigation of immunotherapeutic agents.
The first genetic model to closely resemble DIPG preceded more recent genomic and molecular tumor characterization and was driven by germline Ink4a-ARF deletion and PDGFB overexpression in the Nestin-expressing neural stem cells of the fourth ventricle and aqueduct in neonatal mice . This method utilized the replication-competent avian sarcoma-leucosis virus long-terminal repeat with splice acceptor/tumor virus A (RCAS/Tva) system whereby RCAS-PDGFB-expressing DF1 chicken fibroblast cells were injected into Nestin tv-a;Ink4a-ARF-/- mouse pups at postnatal day 3. Despite very closely representing human DIPG histopathology, tumors do not exclusively arise in the pons. Subsequent variations of this model have since been developed to more closely replicate the genomics of human DIPG. This includes RCAS-PDGFB, RCAS-Cre, RCAS-H3.3K27M expressing DF1 cells intracranially injected into Neastin tv-a;p53lox/lox neonatal mice and RCAS-PDGFB, RCAS-Cre, RCAS-H3.3K27M expressing DF1 cells intracranially injected into Pax3 tv-a;p53lox/lox neonatal mice [39,101]. Most recently, in utero electroporation of the pontine nuclei-containing lower rhombic lip of embryonic day 12.5 mouse embryos with a piggyBac transposon vector to overexpress H3.3K27M in combination with a non-transposable gRNA/Cas9 targeting Trp53 (H3.3K27M;p53 KD) resulted in neoplastic transformation with 100% penetrance 6 months following surgery . Moreover, electroporation of a transposable shRNA targeting ATRX into this same model (H3.3K27M;ATRX/p53 KD) resulted in focally restricted lesions and reduced tumor latency to 4 months whilst the additional overexpression of wildtype PDGFRA cDNA using the piggyBac transposon (H3.3K27M;PDGFRA;ATRX/p53 KD) led to increased invasion and further reduced tumor latency to 21 days . The different histopathological features of these models provide some insight into the importance of co-occurring genomic alterations and aberrant protein interactions on tumorigenesis. Whilst genetic mouse models of DIPG provide the benefit of studying tumors that arise in situ, in immunocompetent animals, they are currently restricted to narrow or broad cells of origin harboring limited and specific genetic alterations and are therefore only representative of a small cohort of the disease. As our understanding of tumor biology and the genetic and molecular interactions underlying DIPG continue to increase, so too will our ability to generate additional models that accurately represent the known heterogeneity of disease.
Comprehensive reviews of DIPG-specific clinical trials have previously been published, analyzing a total of 55 DIPG-specific trials covering the period from 1984 to March 2011 [10,11]. Despite the large number of clinical trials, no clear improvement in either the quality of life or length of survival has been demonstrated, and most studies are, in hindsight, complicated by the wide variance in the selection criteria and absence of accompanying genomic and molecular data. Additionally, a systematic clinical review from the Netherlands has emphasized the necessity of cross-national cooperation to prevent potential epidemiological bias . The pharmacologic agents investigated to date are largely based on therapies proven to convey survival benefit in the treatment of adult gliomas. The only agents with activity against DIPG genomic targets which have been investigated are anti-EGFR tyrosine kinase inhibitors, and results to date are inconclusive, possibly owing to varied selection criteria. One study requiring tissue biopsy on diagnosis, investigated the effects of erlotinib, and achieved an improved median survival of 12months. However, the outcome was reported as inconclusive, and further Phase III studies were deemed necessary to validate the results .
In this review, we have also tabulated clinical trials published between March 2011 to June 2018 (Table 4). The agents investigated are still primarily common chemotherapeutic agents with anti-EGFR agents continuing to be one of the few drug classes being tested targeting known genetic abnormalities in DIPG tumors. Short-term stable disease was reported in an 8-patient clinical trial using a PI3K pathway-specific AKT inhibitor and an mTOR inhibitor, but it failed to improve overall survival. Generic alkylating agents such as temozolomide have been extensively studied in several trials, with no proven survival benefit. Other studies included agents such as VEGF inhibitors and mTOR inhibitors also resulted in negative or inconclusive results (Table 4).
Low drug bioavailability around the tumor due to its anatomical position within the blood brain barrier and its encapsulated morphology has also been proposed as a reason for lack of conclusive and positive outcomes in DIPG clinical trials. As a result, studies are now being undertaken to maximize drug delivery to the site. Besides the conventional chemotherapy delivery through intravenous therapy, other novel routes of drug delivery are being investigated. Of these methods, convection enhanced delivery (CED) has been the most extensively studied with in vivo murine and primate studies proving efficacy of drug delivery [103,104]. CED utilizes a site-directed catheter which delivers a high concentration of the therapeutic agent directly to the tumor bed. This method was developed with the purpose of achieving reliable drug levels of agents with low bioavailability across the blood brain barrier. Although a number of trials have been conducted investigating the application of CED with conventional anticancer treatments, only recently has the delivery of targeted or radioimmunotherapy agents been described for DIPG patients suggesting that it is a safe and rational therapeutic option for these patients [105,106,107,108]. Despite potential barriers to the successful application of CED, including unequal distribution of the drug to variegated tumor tissue and necessity of neurosurgery expertise for its insertion, this is an avenue with promise that warrants further attention.
In addition to CED, several other innovative methods are also on the horizon. These include intranasal chemotherapy administration, drug delivery via continuous interstitial infusions, and through the medium of human neural and mesenchymal stem cells . These ideas are still in the preclinical stages of investigation but have already showed promise in murine experimental models [110,111,112].
In addition to the most recent clinical trials outlined in Table 4, there are also a number of ongoing trials yet to be published (Table 5). Many of these ongoing trials are testing more promising agents targeting a range of different genomic abnormalities specific to DIPG tumors. Their results are much anticipated and will provide a platform on which directed therapeutic regimes can be formed through more comprehensive genomic understanding on a biopsy-oriented, case-specific level.
Table 4 Selected recent DIPG clinical trials with > 5 patients (published from March 2011 – June 2018).
Table 5 WHO registry-listed clinical DIPG drug trials up to June 2018# .
It should be noted that the rarity of DIPG has a significant impact on the ability to accelerate clinical research. The difficulty in recruiting sufficient patient numbers to demonstrate a potential survival advantage necessitates multi-institutional international trials and therefore can restrict the number of simultaneous trials. Accordingly, the weight of preclinical data will play an important role in prioritizing the next wave of clinical investigation.
Given the lack of success in achieving improved patient outcomes for DIPG to date, future focus is on tumor genomic and molecularly-informed targeted therapies and improving drug accessibility to the site of disease. To achieve this, better understanding of the genomic landscape of DIPGs can yet be achieved through improving the protocolization of tissue and liquid biopsies for tumor subtyping, and cross-national collaboration of DIPG research with coordination of DIPG databases, such as the International DIPG Registry and SIOPE DIPG network, to achieve a comprehensive epidemiologic profile for the malignancy.
A greater number of promising preclinical studies focused on DIPG targeted therapies is anticipated in the coming years. This will lay the groundwork on which further translational clinical trials should be conducted. Owing to the complex facets of DIPG, recent preclinical research has expanded to cover a broader range of treatment options as well as adjunct supportive therapies, utilizing both intrinsic and extrinsic pathways to target this tumor.
Extrinsically, recent identification of potential DIPG targeted therapies have put a greater emphasis on targeting the tumor’s unique genomic makeup (Table 2). Historically, DIPG clinical trials have investigated chosen agents based on their effectiveness against anatomically and histologically similar adult counterparts, which have unfortunately failed to demonstrate any clinical success (Table 4). In recent years, a number of promising DIPG genomic-targeting therapeutic agents have been reported with positive outcomes in both in vitro and in vivo murine models (Table 3). Improvements in the numbers and heterogenous representation of preclinical in vitro and in vivo models will significantly enhance the transferability of preclinical results to the clinical setting. Several clinical trials extending from these studies are currently in the recruitment phase. A rationalized approach matching therapies to patient-specific tumor gene and pathway dependencies provides clinical potential for improving quality of life and/or survival outcomes for children with DIPG.
Intrinsically, recent developments in immunotherapy have demonstrated promising results in the utilization and augmentation of the children’s own immune system to target and destroy tumor cells. Recent preclinical investigations of DIPG genomically targeted CAR-T cells have achieved promising in vitro and in vivo results, but are yet to be translated to clinical practice . This may be challenged by the microenvironment of DIPG tumors, which are neither highly immunosuppressive nor inflammatory . Therefore, concurrent research into methods of the delivery, activation, and retention of these cells in the tumor environment will be necessary. However, this area remains one of enormous potential and intense interest.
Owing to the inaccessibility of DIPG’s anatomical location, further development in CNS drug delivery methods and cellular engineering is necessary to improve the potential clinical efficacy of both molecular and cellular agents. In addition to further research into invasive approaches such as CED and infusions, recent developments in non-invasive ultrasound-guided delivery of therapeutic agents through microbubbles could also provide means of accurately targeting tumor cells to maximize therapeutic effect whilst minimizing systemic toxicity. It is also likely that the modification of already established targeted therapies with proven preclinical activity, to increase blood brain barrier permeability, could significantly strengthen the therapeutic arsenal required to treat this disease.
Further research into concurrent treatments such as radiotherapy can also be anticipated in the coming years. Some positive results have been seen in the re-irradiation trials published, and trials of larger numbers will be necessary to investigate the efficacy, dosage and toxicity of additional radiotherapy.
To improve the morbidity and mortality of children with DIPG, it is imperative to develop cross-national/international collaboration in protocoled biopsying and genomic analysis, and the consequent identification and development of genomically informed targeted therapies. Improvements in in vivo models and greater insight into effective methods of drug and cellular delivery will aid in improving efficacy in clinical translation. Together with concurrent radiotherapy and supportive treatments, increasing clinical trials of preclinically tested DIPG targeted therapies has the potential to improve the quality of life and survival outcomes in children with DIPG.
TZ and JEC contributed to the writing of the manuscript. Review and editing was performed by SK, RF and PD.
SK is supported by the Australian Lions Childhood Cancer Research Foundation Fellowship (Children’s Cancer Foundation: Project 215). JEC is supported by Victoria Cancer Agency Mid-Career Fellowship (MCRF17014). Thanks to the Children’s Cancer Foundation and the Isabella and Marcus Foundation for continued support. We also wish to acknowledge the Victorian Government's Operational Infrastructure Support Program. The contents of this manuscript are solely the responsibility of the participating institutions and individual authors, and do not reflect the views of these funding agencies.
The authors have declared that no competing interests exist.